Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates

References

• Schizophrenia. Bethesda, MD, USA. National Institute of Mental Health. 2016. Available at: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. [Last accessed 1 June 2017]
   Google Scholar
• Vos T, Allen C, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015;386:743-800
   PubMed Web of Science ®Google Scholar
• Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet 2016;388:1545-602
   PubMed Web of Science ®Google Scholar
• Abou-Saleh MT, Ghubash R, Daradkeh TK, et al. Alain community psychiatry survey I. Prevalence and socio-demographic correlates. Soc Psychiatry Psychiat Epidemiol 2001;35:20-8
   Google Scholar
• Eapen V, Ghubash R. Help-seeking for mental health problems of children: preferences and attitudes in the united arab emirates. Psychol Rep 2004;94:663-7
   PubMed Web of Science ®Google Scholar
• Sewilam AM, Watson AMM, Kassem AM, et al. Roadmap to reduce stigma of mental illness in the middle east. Int J Soc Psychiatry 2015;61:111-20
   PubMed Web of Science ®Google Scholar
• Shahrour TM, Rehmani RS. Testing psychiatric stigma in general hospital in Saudi Arabia. Saudi Med J 2009;30:1336-9
   PubMed Web of Science ®Google Scholar
• Alkhadhari S, Al Zain N, Darwish T, et al. Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the middle east. Neuropsychiat Dis Treat 2015;11:915-24
   PubMed Web of Science ®Google Scholar
• Llorca PM. Partial compliance in schizophrenia and the impact on the patient outcomes. Psychiatry Res 2008;161:235-47
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ni W. Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy 2015;35:813-22
   PubMed Web of Science ®Google Scholar
• Pilon D, Muser E, Lefebvre P, et al. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry 2017;17:207
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Pharm 2015;21:754-68
   PubMed Web of Science ®Google Scholar
• Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:60-7
   Web of Science ®Google Scholar
• Schreiner A, Aadamsoo K, Carlo Altamura A, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia Res 2015;169:393-9
   PubMed Web of Science ®Google Scholar
• Sermon J, Geerts P, Decuypere F, et al. Treatment continuation and treatment characteristics of 3 long acting antipsychotic medications (paliperidone palmitate, risperidone microspheres and haloperidol decanoate) in Belgium. Poster presented at the International Society of Pharmacoeconomics and Outcomes Research Congress in Milan, Italy; 2015. 7th - 11th November, 2016. Available at: https://www.ispor.org/research_pdfs/48/pdffiles/PMH42.pdf. [Last accessed 1 June 2017]
   Google Scholar
• Denee T, Geerts P, Sermon J, et al. Treatment continuation and treatment characteristics of four long acting antipsychotic medications in the Netherlands. Poster presented at the International Society of Pharmacoeconomics and Outcomes Research Congress in Milan, Italy; 2015. 7th - 11th November, 2016. Available at: https://www.ispor.org/research_pdfs/51/pdffiles/PMH7.pdf. [Last accessed 1 June 2017]
   Google Scholar
• Romero Guillena SL, Mata Saenz B, Fashho Rodriguez E, et al. Paliperidone palmitate versus conventional depots and oral antipsychotics in inpatients with schizophrenia. Poster presented at the European College of Neuropsychopharmacology Congress in Amsterdam, Netherlands; 2015. 29th August - 1st September 2015. Available at: http://www.europeanneuropsychopharmacology.com/article/S0924-977X(15)30688-X/pdf. [Last accessed 1 June 2017]
   Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry 2015;76:554-61
   PubMed Web of Science ®Google Scholar
• Young-Xu Y, Duh MS, Muser E, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia. J Clin Psychiatry 2016;77:e1332-e1341
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 2017;74:686-93
   PubMed Web of Science ®Google Scholar
• Torres-Gonzalez F, Ibanez-Casas I, Saldivia S, et al. Unmet needs in the management of schizophrenia. Neuropsychiat Dis Treat 2014;10:97-110
   PubMed Web of Science ®Google Scholar
• Koçkaya G, Wertheimer A. Pharmaceutical market access in emerging markets. Chapter 6, Market access in the United Arab Emirates and selected Middle Eastern countries; 2016. ISBN = 978-88-97419-63-1.
   Google Scholar
• Vision 2021: World-class healthcare. United Arab Emirates: Government of the United Arab Emirates; 2010. Available at: https://www.vision2021.ae/en/national-priority-areas/world-class-healthcare. [Last accessed 27 November 2017]
   Google Scholar
• Einarson TR, Maia-Lopes S, Goswami P, et al. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. J Me Econ 2016;19:913-21
   PubMed Web of Science ®Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics 2016;34:363-91
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry 2014;68:416-27
   PubMed Web of Science ®Google Scholar
• Einarson TR, Hemels ME. Validation of an economic model of paliperidone palmitate for chronic schizophrenia. J Med Econ 2013;16:1267-74
   PubMedGoogle Scholar
• Einarson TR, Pudas H, Goswami P, et al. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. J Med Econ 2016;19:111-20
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatr 2013;25:85-94
   PubMed Web of Science ®Google Scholar
• Jukic V, Jakovljevic M, Filipcic I, et al. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia. Value Health Region Issues 2013;2:181-8
   PubMedGoogle Scholar
• Hemels MEH, Einarson TR, Zilbershtein R, et al. Cost-effectiveness of injectable atypical long-acting antipsychotics for chronic schizophrenia in Poland. J Health Policy Outcomes Res 2014;2:50-5
   Google Scholar
• Einarson TR, Zilbershtein R, Skoupa J, et al. Economic and clinical comparison of atypical depot antipsychotics drugs for treatment of chronic schizophrenia in the Czech Republic. J Med Econ 2013;16:1089-95
   PubMedGoogle Scholar
• Einarson TR, Geitona M, Chaidemenos A, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry 2012;11:18
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Pat Pref Adher 2013;7:1171-1180
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2010;24(Suppl4):17-25
   Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Oslo, Norway. ATC/DDD Index; 2017. Available at: https://www.whocc.no/atc_ddd_index/. [Last accessed 4 April 2017]
   Google Scholar
• Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee Report. Birmingham, UK: Department of Public Health & Epidemiology, University of Birmingham; 1998. Available at: http://www.birmingham.ac.uk/Documents/college-mds/haps/projects/WMHTAC/REPreports/1998/olanzapine.pdf. [Last accessed 12 July 2017]
   Google Scholar
• Oh PI, Lanctot KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137-56
   Google Scholar
• Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101-8
   PubMed Web of Science ®Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105
   PubMed Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophrenia Res 2004;71:155-165
   PubMed Web of Science ®Google Scholar
• Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. PharmacoEconomics 2010;28:1109-21
   PubMed Web of Science ®Google Scholar
• Dubai Statistics Center. Government of Dubai, United Arab Emirates. 2013 & 2016 Reports. Available at: https://www.dsc.gov.ae/en-us/Themes/Pages/Prices.aspx?Theme=25&year=2015#DSC_Tab1. [Last accessed 5 May 2017]
   Google Scholar
• Drug Price List effective 1st September, 2016, United Arab Emirates: Drug Department, Ministry of Health; 2016. Available at: http://www.cpd-pharma.ae/downloads/Price-List-2016/MOH-Medicines-Price-List-For-official-use-As-on-1st-of-sep-2016.pdf. [Last accessed 20 October 2016]
   Google Scholar
• Zain AA. MoH hospitals increase medical service fees. Filed November 2013. United Arab Emirates: Khaleej Times. Available at: http://www.khaleejtimes.com/nation/uae-health/moh-hospitals-increase-medical-services-fees. [Last accessed 9 May 2017]
   Google Scholar
• Mahboub BH, SMA Shendi FRSMA, Safarini BK, et al. Cost of asthma in Dubai, United Arab Emirates (UAE). J Pulmon Respir Med 2013;3:146
   Google Scholar
• Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effect Res Alloc 2003;1:8
   PubMedGoogle Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull WHO 2016;94:925-30
   PubMed Web of Science ®Google Scholar
• Revill P, Ochalek J, Lomas J, et al. Cost-effectiveness thresholds: guiding health care spending for population health improvement. A report by the Centre for Health Economics, University of York, for the International Decision Support Initiative (iDSI). York, United Kingdom. 2015. Available at: http://www.idsihealth.org/wp-content/uploads/2015/01/CE-Thresholds-iDSI-Working-Group-Final-Report.pdf. [Last accessed 11 June 2017]
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness – the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957-65
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Poster presented at the European College of Neuropsychopharmacology Congress in Paris, France; 2017. 2nd - 5th September 2017. Available at: https://www.ecnp.eu/presentationpdfs/71/P.3.d.015.pdf. [Last accessed 20 November 2017]
   Google Scholar
• Cullen BA, McGinty EE, Zhang Y, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophrenia Bull 2013;39:1159-68
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lonngvist J, Wahlback K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7
   PubMed Web of Science ®Google Scholar
• Velligan DI, Lam YF, Glahn DC, et al. Defining and assessing adherence in oral antipsychotics: a review of the literature. Schizophrenia Bull 2006;32:724-42
   PubMed Web of Science ®Google Scholar
• Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007;58:1187-92
   PubMed Web of Science ®Google Scholar